SR 11302
SR 11302 性质
| 沸点 | 541.6±30.0 °C(Predicted) |
|---|---|
| 密度 | 1.048±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 4.67±0.33(Predicted) |
| 颜色 | 浅黄至黄色 |
SR 11302 用途与合成方法
AP-1
SR 11302 (SR11302) show strong anti-AP-1 activity with selective binding with RARα and RARγ, but not with RARβ and RXRα.
SR 11302 (SR-11302; 1 μM) inhibits AP-1 transcription factor activity and decreases aldosterone levels by 61.9% in hypoxia-treated cells.
SR 11302 (SR-11302; 2 µM; 48 hours) inhibits
Helicobacter pylori
(
H. pylori
)-induced cell proliferation in adenocarcinoma gastric (AGS) cells.
SR 11302 (2 µM; 24 hours) inhibits
H. pylori
-induced expression of β-catenin and c-myc in AGS cells.
SR 11302 (SR11302; low dose 0.5 mg/kg and high dose 1 mg/kg body weight; orally gavaged daily) treatment reduces the total vascular lesion number and lesion size in Vldlr -/- mice in a dose-dependent manner.
| Animal Model: | Vldlr -/- mice |
| Dosage: | Low dose 0.5 mg/kg and high dose 1 mg/kg body weight |
| Administration: | Orally gavaged daily from P5 to P15 |
| Result: | High-dose from P5 to P15 reduced the total vascular lesion number by 48% and decreased the lesion size by 40%, without detectable signs of toxicity in mice, including no change in body weight. |
SR 11302 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-15870 | 1 mg | 609 | ||
| 2024-04-30 | HY-15870 | SR 11302 | 160162-42-5 | 5mg | 1600 |
